期刊
JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY
卷 64, 期 1, 页码 78-83出版社
MOSBY-ELSEVIER
DOI: 10.1016/j.jaad.2009.10.051
关键词
clinical trials; evidence-based medicine; melasma; outcome measure; pigmentation; validation
类别
资金
- Galderma International
Background: The Melasma Area and Severity Index (MAST), the most commonly used outcome measure for melasma, has not been validated. Objective: We sought to determine the reliability and validity of the MASI. Methods: After standardized training, 6 raters independently rated 21 patients with mild to severe melasma once daily over a period of 2 clays to determine intrarater and interrater reliability. Validation was performed by comparing the MASI with the melasma severity scale. The darkness component of the MASI was validated by comparing it with the difference between mexameter scores for affected versus adjacent normal-appearing skin. The area component of the MAST was validated by comparing it with the area of each section of the face determined by computer-based measurement software. Results: The MAST score showed good reliability within and between raters and was found to be valid when compared with the melasma severity scale, mexameter scores, and area measurements. Homogeneity assessment by raters showed the least agreement and can be removed from the MASI score without any loss of reliability. Limitations: Patients were limited to Hispanic, African, and Asian backgrounds. Conclusion: The MASI is a reliable measure of melasma severity. Area of involvement and darkness are sufficient for accurate measurement of the severity of melasma and homogeneity can be eliminated. (J Am Acad Dermatol 2011;64:78-83.)
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据